KR101758400B1 - 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸 - Google Patents

종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸 Download PDF

Info

Publication number
KR101758400B1
KR101758400B1 KR1020127005138A KR20127005138A KR101758400B1 KR 101758400 B1 KR101758400 B1 KR 101758400B1 KR 1020127005138 A KR1020127005138 A KR 1020127005138A KR 20127005138 A KR20127005138 A KR 20127005138A KR 101758400 B1 KR101758400 B1 KR 101758400B1
Authority
KR
South Korea
Prior art keywords
compound
formula
group
disease
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127005138A
Other languages
English (en)
Korean (ko)
Other versions
KR20120055571A (ko
Inventor
옌스 폴만
펠릭스 바흐만
Original Assignee
바실리어 파마슈티카 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바실리어 파마슈티카 아게 filed Critical 바실리어 파마슈티카 아게
Publication of KR20120055571A publication Critical patent/KR20120055571A/ko
Application granted granted Critical
Publication of KR101758400B1 publication Critical patent/KR101758400B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020127005138A 2009-07-27 2010-07-26 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸 Expired - Fee Related KR101758400B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09166469 2009-07-27
EP09166469.8 2009-07-27
PCT/EP2010/060803 WO2011012577A1 (en) 2009-07-27 2010-07-26 Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases

Publications (2)

Publication Number Publication Date
KR20120055571A KR20120055571A (ko) 2012-05-31
KR101758400B1 true KR101758400B1 (ko) 2017-07-14

Family

ID=41226617

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005138A Expired - Fee Related KR101758400B1 (ko) 2009-07-27 2010-07-26 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸

Country Status (24)

Country Link
US (1) US8802858B2 (https=)
EP (1) EP2459553B1 (https=)
JP (1) JP5576485B2 (https=)
KR (1) KR101758400B1 (https=)
CN (1) CN102471329B (https=)
AU (1) AU2010277688B2 (https=)
BR (1) BR112012001817B8 (https=)
CA (1) CA2767875C (https=)
CY (1) CY1115809T1 (https=)
DK (1) DK2459553T3 (https=)
EA (1) EA021380B1 (https=)
ES (1) ES2524119T3 (https=)
HR (1) HRP20141120T1 (https=)
IL (1) IL217195A (https=)
MX (1) MX336240B (https=)
NZ (1) NZ597376A (https=)
PL (1) PL2459553T3 (https=)
PT (1) PT2459553E (https=)
RS (1) RS53679B1 (https=)
SI (1) SI2459553T1 (https=)
TW (1) TWI457337B (https=)
UA (1) UA106763C2 (https=)
WO (1) WO2011012577A1 (https=)
ZA (1) ZA201200228B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012098203A1 (en) 2011-01-21 2012-07-26 Basilea Pharmaceutica Ag Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles
CA2822491C (en) * 2011-01-21 2023-02-14 Basilea Pharmaceutica Ag Bubr1 as a biomarker for furazanobenzimidazoles
JP6302674B2 (ja) * 2011-01-21 2018-03-28 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのスタスミンの使用
PT2678679T (pt) 2011-02-24 2017-04-07 Basilea Pharmaceutica Ag Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos
EP2691533B1 (en) * 2011-03-29 2017-04-05 Basilea Pharmaceutica AG Use of phospho-akt as a biomarker of drug response
US9558575B2 (en) 2012-02-28 2017-01-31 Blackberry Limited Methods and devices for selecting objects in images
ITRM20130248A1 (it) * 2013-04-24 2014-10-25 Medivis S R L Formulazioni di riboflavina per il cross-linking transepiteliale.
WO2015173341A1 (en) * 2014-05-13 2015-11-19 Basilea Pharmaceutica Ag Dosage principle for anti-cancer furazanylbenzimidazoles
WO2017068182A1 (en) 2015-10-22 2017-04-27 Basilea Pharmaceutica Ag Use of eb1 as a biomarker of drug response
JP2020517608A (ja) * 2017-04-20 2020-06-18 ピーアイ インダストリーズ リミテッドＰｉ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ 新規フェニルアミン化合物
MX2021011775A (es) * 2017-04-26 2023-01-10 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
US11633383B2 (en) * 2017-05-16 2023-04-25 Basilea Pharmaceutica International AG Dosage principle for drugs useful for treating neoplastic diseases
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2020058405A1 (en) 2018-09-20 2020-03-26 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
CN111454254B (zh) * 2020-04-26 2023-06-02 云白药征武科技(上海)有限公司 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用
CN111423429A (zh) * 2020-05-19 2020-07-17 江西科技师范大学 苯并咪唑联呋咱类系列化合物及其合成方法
WO2022053549A1 (en) 2020-09-10 2022-03-17 Basilea Pharmaceutica International AG Use of c-myc as a biomarker of drug response

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103994A1 (en) 2003-05-23 2004-12-02 Basilea Pharmaceutica Ag Furazanobenzimidazoles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
EP1472245A2 (en) * 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
EP1723138B1 (en) * 2004-02-11 2010-07-14 Basilea Pharmaceutica AG Substituted benzimidazoles and their use for inducing apoptosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103994A1 (en) 2003-05-23 2004-12-02 Basilea Pharmaceutica Ag Furazanobenzimidazoles

Also Published As

Publication number Publication date
HRP20141120T1 (hr) 2015-01-30
BR112012001817B8 (pt) 2021-05-25
CA2767875C (en) 2016-03-15
MX2012000611A (es) 2012-01-27
EP2459553B1 (en) 2014-10-01
EP2459553A1 (en) 2012-06-06
CN102471329A (zh) 2012-05-23
RS53679B1 (sr) 2015-04-30
JP2013500304A (ja) 2013-01-07
JP5576485B2 (ja) 2014-08-20
DK2459553T3 (da) 2014-11-03
CY1115809T1 (el) 2017-01-25
TWI457337B (zh) 2014-10-21
US20120264792A1 (en) 2012-10-18
AU2010277688A1 (en) 2012-02-09
EA021380B1 (ru) 2015-06-30
PT2459553E (pt) 2014-11-24
WO2011012577A1 (en) 2011-02-03
MX336240B (es) 2016-01-13
CN102471329B (zh) 2014-11-05
BR112012001817A2 (pt) 2016-03-15
US8802858B2 (en) 2014-08-12
IL217195A (en) 2014-03-31
ES2524119T3 (es) 2014-12-04
HK1166316A1 (en) 2012-10-26
BR112012001817B1 (pt) 2020-09-29
UA106763C2 (uk) 2014-10-10
NZ597376A (en) 2014-01-31
ZA201200228B (en) 2012-09-26
KR20120055571A (ko) 2012-05-31
SI2459553T1 (sl) 2015-01-30
TW201107318A (en) 2011-03-01
AU2010277688B2 (en) 2013-12-05
PL2459553T3 (pl) 2015-03-31
EA201200189A1 (ru) 2012-08-30
CA2767875A1 (en) 2011-02-03
IL217195A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
KR101758400B1 (ko) 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸
JP6964096B2 (ja) ３−オキソ−２，６−ジフェニル−２，３−ジヒドロピリダジン−４−カルボキサミド類
KR101873672B1 (ko) Ｉｄｏ１ 억제제로서 사용하기 위한 피롤리딘-２,５-디온 유도체, 제약 조성물 및 방법
WO2004022553A1 (de) INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IλB-KINASE
CN103237799A (zh) 杂环衍生物、制备方法及其药学用途
CN110240629A (zh) 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
WO2016104617A1 (ja) キノリン誘導体
CN114230565A (zh) 5-取代吲哚3-酰胺衍生物及其制备方法和用途
AU2015394628A1 (en) Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity
WO2020181386A1 (en) Fluorinated benzo[f]benzimidazol-4-9-dione ium derivatives and pharmaceutical compositions thereof and their use as survivin suppressants
JPWO2016039398A1 (ja) 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物
JP4890270B2 (ja) 置換ベンゾイミダゾール及びアポトーシスを誘導するためのこれらの使用
CN102688234B (zh) 吲哚酮衍生物作为rsk2抑制剂的合成与应用
CN111548286B (zh) 一种具有hdac3抑制活性的psa衍生物及其应用
HK1166316B (en) Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases
ES2719790T3 (es) Acidos ftalámicos N-sustituidos-5 sustituidos como inhibidores de la sortilina
CN121824433A (zh) 一种解旋酶抑制剂、其制备方法及其用途
JP2008308434A (ja) １，３−ベンゾチアジノン誘導体およびその用途
JPH07188181A (ja) グルタミナーゼ阻害剤
HK40045137B (zh) Smad3抑制剂
WO2006090698A1 (ja) キナーゼ阻害薬およびその用途
HK1249499B (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250711

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250711